Effect of Silodosin versus Tamsulosin in the Treatment of Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: Review Article

Background: In this research, the efficacy of silodosin as well as tamsulosin in treatinglower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). LUTS is a big clinical problem for men with BPH, the most frequent progressing illness in older men. BPH has a considerable influence on quality of life. The impacts of growth factors, estrogens, and androgens on prostate enlargement and the onset of symptoms are the primary foci of this investigation into the pathophysiology of BPH. Two regularly used drugs include tamsulosin, a selective α1A & α1D-blocker and silodosin, a highly selective α1A-adrenergic receptor antagonist. The smooth muscles in the prostate in addition to bladder neck are relaxed by the combined action of the two drugs, which helps to reduce pain and increase urine flow. However, silodosin's higher selectivity for the α1A receptor offers the advantage of fewer cardiovascular side effects, making it particularly suitable for patients with cardiovascular comorbidities. Objective: This review article aimed to assess the efficiency of silodosin and tamsulosin in the treatment of LUTS that are linked to BPH. Methods: We searched Google Scholar, Science Direct, PubMed and other online databases for LUTS, BPH, Silodosin and Tamsulosin. The authors also reviewed references from pertinent literature, however only the most recent or comprehensive studies from 1983 to 2011 were included. Documents in languages other than English were disqualified due to lack of translation-related sources. Papers such as unpublished manuscripts, oral presentations, conference abstracts, and dissertations that were not part of larger scientific studies were excluded.Conclusion: The study assessed clinical outcomes such as symptom relief, post-void residual volume reduction, and adverse events. Results indicated that both medications effectively alleviate LUTS, but silodosin demonstrated a better safety profile concerning cardiovascular effects. Common side effects involved dizziness, nasal congestion, and retrograde ejaculation, with silodosin showing a lower incidence of hypotension contrasted with tamsulosin. In conclusion, while both silodosin and tamsulosin are effective in managing LUTS associated with BPH, silodosin’s superior selectivity and lower risk of cardiovascular complications make it a preferred option for certain patient populations. Tailoring treatment based on individual patient profiles can enhance therapeutic outcomes and quality of life.